0000899243-20-025640.txt : 20200917 0000899243-20-025640.hdr.sgml : 20200917 20200917214802 ACCESSION NUMBER: 0000899243-20-025640 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200915 FILED AS OF DATE: 20200917 DATE AS OF CHANGE: 20200917 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galimi Francesco CENTRAL INDEX KEY: 0001823996 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 201182671 MAIL ADDRESS: STREET 1: 12930 VIA ESPERIA CITY: DEL MAR STATE: CA ZIP: 92014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 BOYLSTON STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 500 BOYLSTON STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-15 0 0001720580 Adicet Bio, Inc. ACET 0001823996 Galimi Francesco C/O ADICET BIO, INC. 500 BOYLSTON STREET, 13TH FLOOR BOSTON MA 02116 0 1 0 0 Chief Medical Officer Employee Stock Option (right to buy) 5.97 2020-09-15 4 A 0 128424 A 2029-10-15 Common Stock 128424 128424 D Incentive Stock Option (right to buy) 16.11 2020-09-17 4 A 0 77269 0.00 A 2030-09-16 Common Stock 77269 77269 D 25% of the option will vest on September 23, 2020, and 1/36th of the remaining unvested option will vest on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date. Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc." 1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Dr. Galimi remains in continuous service as of the applicable vesting date. Senior Vice President and Chief Medical Officer /s/ Nick Harvey, Attorney-in-Fact for Francesco Galimi 2020-09-17